|1.||Takemura, G: 2 articles (07/2001 - 01/2000)|
|2.||Uno, Y: 2 articles (07/2001 - 01/2000)|
|3.||Arai, M: 2 articles (07/2001 - 01/2000)|
|4.||Wang, N: 2 articles (07/2001 - 01/2000)|
|5.||Minatoguchi, S: 2 articles (07/2001 - 01/2000)|
|6.||Nishida, Y: 2 articles (07/2001 - 01/2000)|
|7.||Fujiwara, T: 2 articles (07/2001 - 01/2000)|
|8.||Fujiwara, H: 2 articles (07/2001 - 01/2000)|
|9.||Hashimoto, K: 2 articles (07/2001 - 01/2000)|
|10.||Hashimoto, Y: 1 article (07/2001)|
|1.||Left Ventricular Dysfunction
01/01/2000 - "Preischemic treatment with MOR-14 is protective against postischemic left ventricular dysfunction through the inhibition of glycogenolysis in the isolated rat heart."
01/01/2000 - "We examined whether pharmacological inhibition of glycogenolysis by N-methyl-1-deoxynojirimycin (MOR-14), a new compound which reduces the glycogenolytic rate by inhibiting the alpha-1,6-glucosidase activity of the glycogen-debranching enzyme, can protect the heart against postischemic left ventricular dysfunction. "
01/01/2000 - "N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction."
08/15/1986 - "Effects of tunicamycin, N-methyl-1-deoxynojirimycin, and manno-1-deoxynojirimycin on the biosynthesis of lactosaminoglycans in F9 teratocarcinoma cells."
12/05/1986 - "We have previously shown that the glucosidase inhibitor, N-methyl-1-deoxynojirimycin (MedJN), only partially inhibited N-linked complex oligosaccharide biosynthesis in F9 teratocarcinoma cells whereas the alpha-mannosidase I inhibitor, manno-1-deoxynojirimycin, completely prevented this synthesis (Romero, P. "
07/01/2001 - "Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits."
07/01/2001 - "N-methyl-1-deoxynojirimycin (NMDN), an a-glucosidase inhibitor, reduces myocardial infarct size by reducing the glycogenolytic rate through inhibition of the alpha-1,6-glucosidase of glycogen-debranching enzyme in the heart, in addition to possessing an antihyperglycemic action by blocking alpha-1,4-glucosidase in the intestine. "
04/07/1998 - "Preischemic treatment with MOR-14 preserved glycogen, attenuated the accumulation of lactate, and reduced the myocardial infarct size by 69%. "
|4.||Melanoma (Melanoma, Malignant)
08/01/1995 - "Finally, when melanoma cells are treated with inhibitors of carbohydrate processing, such as N-methyl-1-deoxynojirimycin, 1-deoxymannojirimycin and swainsonine, they still secrete a motility-stimulating autotaxin. "
01/25/1989 - "Treatment of M21 human melanoma cells with the glucosidase inhibitors castanospermine, 1-deoxynojirimycin, or N-methyldeoxynojirimycin results in a dose-dependent inhibition of glycosaminoglycan (GAG) addition to the melanoma antigen recognized by monoclonal antibody 9.2.27. "
01/25/1989 - "The use of agents which block discrete steps in the trimming and processing of core oligosaccharides (castanospermine, 1-deoxynojirimycin, N-methyldeoxynojirimycin, 1-deoxymannojirimycin, and swainsonine) demonstrates that removal of glucose residues from the N-linked oligosaccharides is required for the cell surface expression of a melanoma proteoglycan core protein and for the conversion of the core protein to a chondroitin sulfate proteoglycan. "
04/07/1998 - "Another 40 rabbits given 100 mg of MOR-14 or saline 10 minutes before ischemia were euthanized at 10 or 30 minutes of ischemia for biochemical analysis. "
01/01/2000 - "MOR-14 significantly preserved the glycogen content and significantly attenuated the lactate accumulation during the 30-min episode of ischemia. "
01/01/2000 - "In another series of experiments, the myocardial content of glycogen and lactate was measured during the 30-min episode of ischemia in groups treated with and without 2mM of MOR-14. "
04/07/1998 - "MOR-14 decreased the alpha-1,6-glucosidase activity to approximately 20% in vivo, reduced the glycogen breakdown, and attenuated the lactate accumulation at both 10 and 30 minutes of ischemia. "
|1.||1-Deoxynojirimycin (1 Deoxynojirimycin)
|5.||Glycogen Debranching Enzyme System (Glycogen Debranching Enzyme)
|10.||Chondroitin Sulfate Proteoglycans